Skarpen E, et al. (2005) Altered regulation of EGF receptor signaling following a partial hepatectomy. J Cell Physiol 202, 707-16 15389569

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T679-p - EGFR (rat) ▲

Modsite: RQLVRKRtLRRLLQE SwissProt Entrez-Gene Orthologous residues EGFR (human): T678‑p, EGFR iso2 (human): ‑, EGFR iso5 (human): T678‑p, EGFR (mouse): T680‑p, EGFR (rat): T679‑p, EGFR (pig): T678‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  hepatocyte, liver Cellular systems studied:  primary cells, tissue Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes partial_hepatectomy increase phorbol_ester increase

Y1017-p - EGFR (rat) ▲

Modsite: DVVDADEyLIPQQGF SwissProt Entrez-Gene Orthologous residues EGFR (human): Y1016‑p, EGFR iso2 (human): ‑, EGFR iso5 (human): Y1016‑p, EGFR (mouse): Y1018‑p, EGFR (rat): Y1017‑p, EGFR (pig): Y1016‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  hepatocyte, liver Cellular systems studied:  primary cells, tissue Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes EGF increase partial_hepatectomy EGF inhibit treatment-induced increase partial_hepatectomy no change compared to control

Y1091-p - EGFR (rat) ▲

Modsite: TFLPVPEyINQSVPK SwissProt Entrez-Gene Orthologous residues EGFR (human): Y1092‑p, EGFR iso2 (human): ‑, EGFR iso5 (human): ‑, EGFR (mouse): Y1092‑p, EGFR (rat): Y1091‑p, EGFR (pig): Y1091‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  hepatocyte, liver Cellular systems studied:  primary cells, tissue Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes EGF increase partial_hepatectomy EGF inhibit treatment-induced increase partial_hepatectomy no change compared to control

Y1109-p - EGFR (rat) ▲

Modsite: GsVQNPVyHNQPLHP SwissProt Entrez-Gene Orthologous residues EGFR (human): Y1110‑p, EGFR iso2 (human): ‑, EGFR iso5 (human): ‑, EGFR (mouse): Y1110‑p, EGFR (rat): Y1109‑p, EGFR (pig): Y1109‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  hepatocyte, liver Cellular systems studied:  primary cells, tissue Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes EGF increase partial_hepatectomy EGF inhibit treatment-induced increase partial_hepatectomy no change compared to control

Y1171-p - EGFR (rat) ▲

Modsite: MSLDNPDyQQDFFPK SwissProt Entrez-Gene Orthologous residues EGFR (human): Y1172‑p, EGFR iso2 (human): ‑, EGFR iso5 (human): ‑, EGFR (mouse): Y1172‑p, EGFR (rat): Y1171‑p, EGFR (pig): Y1171‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  hepatocyte, liver Cellular systems studied:  primary cells, tissue Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes EGF increase partial_hepatectomy EGF inhibit treatment-induced increase partial_hepatectomy no change compared to control

Y1196-p - EGFR (rat) ▲

Modsite: PTAENAEyLRVAPPS SwissProt Entrez-Gene Orthologous residues EGFR (human): Y1197‑p, EGFR iso2 (human): ‑, EGFR iso5 (human): ‑, EGFR (mouse): Y1197‑p, EGFR (rat): Y1196‑p, EGFR (pig): Y1196‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  hepatocyte, liver Cellular systems studied:  primary cells, tissue Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes EGF increase partial_hepatectomy EGF inhibit treatment-induced increase phorbol_ester EGF inhibit treatment-induced increase partial_hepatectomy no change compared to control